Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Description:
Host: Aditya Bardia, MD
Host: Tiffany Traina, MD, FASCO
When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!